Date: 2015-12-11
Type of information: Private placement
Company: Kite Pharma (USA - CA)
Investors:
Amount: $287.6 million
Funding type: private placement
Planned used:
Others: * On December 11, 2015, Kite Pharma announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 543,750 shares of Kite\'s common stock. Including this option exercise, total gross proceeds to Kite from the offering of an aggregate 4,168,750 shares at a price to the public of $69.00 per share will be approximately $287.6 million , before deducting the underwriting discounts and commissions and other offering expenses. The offering is expected to close on December 15, 2015 , subject to customary closing conditions. * On December 10, 2015, Kite Pharma announced the pricing of an underwritten public offering of 3,625,000 shares of its common stock at a price to the public of $69.00 per share. The gross proceeds to Kite from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $250.1 million . The offering is expected to close on or about December 15, 2015 , subject to customary closing conditions. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 543,750 shares of its common stock at the public offering price, less the underwriting discounts and commissions. * On December 8, 2015, Kite Pharma announced that it has commenced an underwritten public offering of approximately $250 million of shares of its common stock. Kite expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. All shares of common stock to be sold in the offering will be offered by Kite. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies LLC and Citigroup Global Markets Inc. are acting as lead book-running managers for the offering. Cowen and Company, LLC and RBC Capital Markets, LLC are acting as joint book-running managers, and Stifel is acting as co-manager.
Therapeutic area: Cancer - Oncology - Rare diseases
